This protective enzyme could help stop fatty liver disease from getting worse

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-10-03T13:54:09.008Z • Permanent link

Scientists at the University of California, Los Angeles (UCLA) have identified an enzyme that may act as a natural defense against the worsening of fatty liver disease, which affects an estimated 100 million Americans. According to researchers, Dr. Jianping Fu, a molecular biologist at UCLA, and his team have discovered a new enzyme called UBE2N, which helps liver cells clear away damaged mitochondria and break down toxic substances.

Dr. Fu's team has been studying the effects of UBE2N on liver cells for several years, and their research has shown that the enzyme can protect liver cells from damage caused by excessive fat accumulation. The researchers believe that UBE2N may be a key player in preventing the progression of fatty liver disease, which is a major risk factor for liver cancer, diabetes, and cardiovascular disease.

The research was published in a recent issue of the journal Nature Communications, and Dr. Fu's team has already begun working with pharmaceutical companies to develop new treatments based on their findings. One company, Biogen, has announced plans to develop a new treatment for fatty liver disease using UBE2N as its active ingredient. The company's CEO, George A. Smoot, has stated that the company is "excited about the potential of UBE2N to treat this devastating disease.

The discovery of UBE2N has significant implications for the AI and tech ecosystem, particularly for companies that are developing new treatments for fatty liver disease. For example, companies such as Gilead Sciences and AbbVie have already announced plans to develop new treatments for the disease, and the discovery of UBE2N may provide them with a key ingredient in their treatments.

The research community is also closely watching the development of UBE2N-based treatments, as it has the potential to revolutionize the way that we treat fatty liver disease. Researchers at institutions such as Harvard University and Stanford University are already working on studies to further understand the effects of UBE2N on liver cells, and the results of these studies will be crucial in determining whether UBE2N-based treatments are effective.

Furthermore, the discovery of UBE2N has significant implications for the pharmaceutical industry as a whole. The development of new treatments for fatty liver disease is a major priority for the industry, and the discovery of UBE2N provides a promising new lead. Companies such as Pfizer and Johnson & Johnson are already working on new treatments for the disease, and the discovery of UBE2N may provide them with a key ingredient in their treatments.